Bionaturis develops a breakthrough drug for livestock

Bionaturis (ticker BNT-MAB), an international reference company providing biological drugs, has just signed a new collaborative agreement with a multinational company to develop a new product that meets an increasing need of the livestock industry. It is a new first-in-class drug to induce ovulation in livestock prior to artificial insemination.

According to the agreement, Bionaturis will make use of its proprietary system FLYLIFE to develop the product and will also perform efficacy and safety tests in animal models, while the multinational will validate these results in its facilities, performing field trials with the intended specie.

The agreement includes exclusive licensing option rights for the multinational company, which forecasts a minimum potential market of 20-25 USD million for this product.

Victor Infante, Bionaturis’ CEO, commented: “The goal of this collaborative development program is to enable the multinational company to replace the current standard treatment with a safe, cost-effective, scalable recombinant first-in-class solution produced by our technology.”

The new agreement represents another important milestone for Bionaturis in its goal of reaching co-development agreements with large international laboratories and standardize its FLYLIFE platform as reliable alternative system of making cutting-edge medicines.


FLYLIFE platform

FLYLIFE is a revolutionary Plug&Play platform designed to produce cost-effective biological drugs at an industrial scale.

Bionaturis offers product licenses, based on its proprietary FLYLIFE platform, providing partners full support for protein therapeutics and vaccines development. 

June 24th, 2014|Hechos Relevantes, Press english|0 Comments

Bionaturis starts work on oral fish farm vaccine

A Spanish biotech firm is starting up a new project to develop better vaccination programs in fish farms to protect against livestock diseases. Bionaturis is running the project, together with Cadiz University’s department of chemical engineering, food technology and environmental sciences, and the Andalusian Aquaculture Technological Centre Foundation.

“We will develop vaccines and other types of treatment to be administered orally in a safe and efficient way for some of the main pathogens that currently affect aquaculture,” said Ana de las Heras, who will supervise the project.

Reed more in

January 5th, 2013|last news, Press english|0 Comments

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.